Allegra Sarah, Comità Stefano, Roetto Antonella, De Francia Silvia
Department of Clinical and Biological Sciences, University of Turin, San Luigi Gonzaga University Hospital, 10043 Orbassano, Italy.
Biomedicines. 2024 Dec 18;12(12):2885. doi: 10.3390/biomedicines12122885.
BACKGROUND/OBJECTIVES: In the absence of physiological mechanisms to excrete excessive iron, the administration of iron chelation therapy is necessary. Age and hormones have an impact on the absorption, distribution, metabolism, and excretion of the medications used to treat iron excess, resulting in notable sex- and gender-related variances.
Here, we aimed to review the literature on sex and gender in iron overload assessment and treatment.
The development of iron chelators has shown to be a successful therapy for lowering the body's iron levels and averting the tissue damage and organ failure that follows. Numerous studies have described how individual factors can impact chelation treatment, potentially impact therapeutic response, and/or result in inadequate chelation or elevated toxicity; however, most of these data have not considered male and female patients as different groups, and particularly, the effect of hormonal variations in women have never been considered.
An effective iron chelation treatment should take into account sex and gender differences.
背景/目的:由于缺乏排泄过量铁的生理机制,因此有必要进行铁螯合治疗。年龄和激素会影响用于治疗铁过量的药物的吸收、分布、代谢和排泄,从而导致明显的性别差异。
在此,我们旨在综述关于铁过载评估和治疗中性别方面的文献。
铁螯合剂的研发已被证明是一种成功的疗法,可降低体内铁水平,并避免随之而来的组织损伤和器官衰竭。许多研究描述了个体因素如何影响螯合治疗、潜在影响治疗反应,和/或导致螯合不足或毒性升高;然而,这些数据大多未将男性和女性患者视为不同群体,特别是从未考虑过女性激素变化的影响。
有效的铁螯合治疗应考虑性别差异。